Claritev earnings date
Want to see CTEV full AI Analyst Report?
Claritev (CTEV) Q3 2026 Earnings Report
CTEV Q3 2026 EPS Results
- Actual EPS
- -$3.64
- Consensus EPS
- -$3.63
- Beat/Miss
- Missed by -$0.01
- One Year Ago EPS
- -$4.23
CTEV Q3 2026 Revenue Results
- Actual Revenue
- $268.31M
- Expected Revenue
- $256.13M
- Beat/Miss
- Beat by +$12.18M
- YoY Revenue Growth
- +9.09%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/09/2026
- Time
- Before Open
- Conference Call
- Monday, November 9, 2026
Claritev's next earnings date is estimated for March 2, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive. Management reported revenue, adjusted EBITDA, bookings, pipeline, client additions, claims activity, and cash-flow expectations that exceeded or improved against prior expectations. The company also raised full-year guidance, projected at least $1.1 billion of revenue in 2027, and highlighted diversification, AI deployment, and product innovation. Offsetting concerns included lower adjusted EBITDA margin, declines in Network and Payment & Revenue Integrity revenue, third-quarter free cash flow usage, 7.7x net leverage, and continued uncertainty around NSA rule changes, but the positive developments significantly outweighed the challenges.
Claritev raised full year revenue guidance to $1.038 billion to $1.043 billion, implying full year revenue growth of 7.5% to 8% and Q4 revenues of $270 million at the midpoint, a low single-digit sequential increase and 9.5% growth over Q4 '25; adjusted EBITDA guidance is $625 million to $630 million, free cash flow guidance is $10 million to $20 million, and capital expenditure guidance is $165 million to $170 million. Q4 operating cash flow is expected to be $110 million to $120 million, with growth of 66% to 81% year-over-year, and free cash flow is expected to be $74 million to $84 million, with growth of 103% to 131%; full year '26 cash conversion is expected to be greater than 50%. ACV bookings are expected to be $115 million to $125 million for the full year, representing 70% to 90% growth over '25. For '27, Claritev expects to achieve at least $1.1 billion of revenue, expects Payment & Revenue Integrity to return to growth, expects Network to be up about 5% excluding the onetime revenue this year, and plans to provide more comprehensive adjusted EBITDA and free cash flow guidance in February while maintaining a high [ SAU ] ratio.
- Revenue and Adjusted EBITDA Beat ExpectationsThird-quarter revenue and adjusted EBITDA exceeded internal expectations. Revenue was $268.3 million, up 9.1% year-over-year and 4.2% sequentially, marking the sixth consecutive quarter of year-over-year revenue growth and the highest quarterly revenue in 17 quarters.
- Raised Full-Year Revenue and EBITDA GuidanceFull-year revenue guidance was raised to $1.038 billion to $1.043 billion, a $30.5 million increase at the midpoint from previous guidance, implying 7.5% to 8% growth. Adjusted EBITDA guidance was raised to $625 million to $630 million, an increase of $12.5 million at the midpoint.
- Strong Bookings Growth and DiversificationClaritev booked $27 million of ACV in Q3, bringing year-to-date bookings to more than $100 million compared with $67 million for the full year 2025. Full-year ACV bookings guidance was raised to $115 million to $125 million, representing 70% to 90% growth over 2025. More than 50% of bookings came from verticals outside the core payer market, including 26% from TPA and another 25% from newer markets primarily consisting of provider, public sector, and international.
- Expansion of Client Base and PipelineClaritev added 5 new client logos in Q3, bringing the two-year total to 46 net new clients. The company said bookings and pipeline are growing across every vertical market, and pipeline growth was approximately 60% year-over-year, with less than half coming from the payer market.
- Claims Intelligence GrowthClaims Intelligence revenue grew 17.1% year-over-year, primarily reflecting incremental NSA volumes associated with an early 2026 client win. Management described Claims Intelligence as the company's largest business and said it has been performing exceedingly well.
- NSA and Surprise Bill Services MomentumNSA was again a key driver of outperformance, with Q3 dispute initiations up 75% year-over-year. NSA claims volumes also grew sequentially, and management said it expects the tailwind to persist. Claritev reported performance 8% better than the industry average in this area.
- Healthy Claims Activity and Savings ValuePSAV claims volumes increased 8% year-over-year and were flat sequentially. Submitted charges grew 15% year-over-year, identified potential savings per claim increased more than 13%, PSAV savings dollars eclipsed $5 billion for the first time in approximately 4 or 5 years, and the company delivered more than $1,500 of savings per claim.
- Record Adjusted EBITDA and Improved Year-to-Date Cash FlowQ3 adjusted EBITDA was $162 million, up 4.4% year-over-year and 4% sequentially, representing the highest quarterly absolute dollar adjusted EBITDA in 16 quarters. For the first nine months, operating cash flow increased 27% to $65 million, unlevered free cash flow increased 16% to $230.7 million, and adjusted cash conversion improved to 50% from 44%.
- Revenue Milestone and Long-Term Growth OutlookTrailing 12-month revenue exceeded $1 billion for the first time since Q1 2023. Management said it now expects to achieve at least $1.1 billion of revenue in 2027, one year earlier than the $1.1 billion revenue target previously contemplated for 2028.
- Positive Fourth-Quarter Cash Flow OutlookThe company expects Q4 operating cash flow of $110 million to $120 million, representing growth of 66% to 81% year-over-year, and free cash flow of $74 million to $84 million, representing growth of 103% to 131%. Management said this would be its strongest free cash flow-generating quarter in more than 4 years and would support a return to positive full-year free cash flow.
- Product Innovation and Medicare Advantage OfferingAt its client conference, Claritev introduced a Medicare Advantage offering combining more than 15 existing payment integrity and network solutions. The company also showcased transparency-based pricing, its newest Claims Intelligence offering, and Claritev Healthcare Intelligence.
- AI Platform and Agent DeploymentClaritev Healthcare Intelligence includes an AI agent called Clara that provides real-time insights into cost trends and drivers using data already held for clients. The company said dozens of AI agents are already in production, with many more in progress, and that it has 4 dozen AI scientists. Management also said 53% of code in Q1 was delivered using AI and expected that figure to reach between 60% to 80% by the end of the year.
- Continued Investment in Growth and TransformationManagement said it is continuing to invest in sales, marketing, go-to-market, delivery, AI, and its Vision 2030 transformation. The company expected approximately $20 million to $25 million of investment in sales, marketing, go-to-market, and delivery during the year, while R&D as a percentage of revenue was expected to trend down from approximately 16.5% in 2025 to about 16% in 2026.
- Payment and Revenue Integrity Bookings PositionClaritev booked more than $40 million of ACV in Payment & Revenue Integrity over the last four quarters, primarily in higher-value categories and newer solutions. Approximately 20% had converted into revenue, and management said it expects the business to return to growth in 2027.
- Network Underlying GrowthManagement said the Network business would be up approximately 5% if the previously disclosed non-recurring revenue were excluded.
CTEV Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 02, 2027 | 2026 (Q4) | -3.19- | -4.88 | ― | ― |
| Nov 09, 2026 | 2026 (Q3) | -3.63-3.64 | -4.23 | 13.95% (+0.59) | |
| Aug 07, 2026 | 2026 (Q2) | -4.12-3.49 | -3.81 | 8.40% (+0.32) | |
| May 07, 2026 | 2026 (Q1) | -4.09-4.41 | -4.38 | -0.68% (-0.03) | |
| Feb 23, 2026 | 2025 (Q4) | -2.79-4.88 | -8.82 | 44.67% (+3.94) | |
| Nov 07, 2025 | 2025 (Q3) | -3.59-4.23 | -24.25 | 82.56% (+20.02) | |
| Aug 06, 2025 | 2025 (Q2) | -1.45-3.81 | -35.6 | 89.30% (+31.79) | |
| May 08, 2025 | 2025 (Q1) | -3.12-4.38 | -33.2 | 86.81% (+28.82) | |
| Feb 25, 2025 | 2024 (Q4) | -9.81-8.82 | -1.6 | -451.25% (-7.22) | |
| Nov 05, 2024 | 2024 (Q3) | -2.75-24.25 | -1.6 | -1415.63% (-22.65) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


